Charani Ranasinghe Selected Research

Infections

1/2021	STAT3 determines IL-4 signalling outcomes in naïve T cells.
1/2018	Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.
10/2017	Heparan sulfate as a receptor for poxvirus infections and as a target for antiviral agents.
1/2014	Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.
1/2014	Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccination.
1/2013	Reduced interleukin-4 receptor α expression on CD8+ T cells correlates with higher quality anti-viral immunity.
11/2012	Role of novel type I interferon epsilon in viral infection and mucosal immunity.
8/2011	Evaluating vaccinia virus cytokine co-expression in TLR GKO mice.
3/2011	Human immunodeficiency virus-1 vaccine design: where do we go now?
10/2005	Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charani Ranasinghe Research Topics

Disease

10	Infections 01/2021 - 10/2005
8	Virus Diseases (Viral Diseases) 01/2021 - 11/2012
3	Vaccinia 01/2020 - 01/2019
3	Fowlpox 01/2018 - 07/2006
2	COVID-19 10/2021 - 01/2021
2	Human Influenza (Influenza) 01/2021 - 10/2014
2	Persistent Infection 09/2014 - 09/2013
1	Cytokine Release Syndrome 01/2021
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2019
1	Poxviridae Infections 10/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2014
1	Atopic Dermatitis (Atopic Eczema) 08/2014
1	Neoplasms (Cancer) 08/2014
1	Inflammation (Inflammations) 08/2014
1	Chronic Disease (Chronic Diseases) 01/2014
1	Tuberculosis (Tuberculoses) 11/2012
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 11/2012
1	Coinfection 08/2011
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2006

Drug/Important Bio-Agent (IBA)

15	VaccinesIBA 10/2021 - 01/2006
5	Interleukin-13IBA 01/2021 - 01/2013
4	CytokinesIBA 01/2021 - 08/2011
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2006
4	AntigensIBA 01/2019 - 07/2006
3	Interleukin-4 (Interleukin 4)IBA 01/2021 - 01/2013
3	Antiviral Agents (Antivirals)IBA 01/2018 - 08/2011
3	InterferonsIBA 01/2013 - 08/2011
2	Subunit VaccinesIBA 10/2021 - 01/2021
2	InterleukinsIBA 01/2021 - 01/2013
2	Interferon Type IIBA 01/2014 - 11/2012
1	Glycoproteins (Glycoprotein)IBA 10/2021
1	Neutralizing AntibodiesIBA 01/2021
1	Aluminum Hydroxide (Algeldrate)FDA Link 01/2021
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2019
1	Interleukin-22 (IL-22)IBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	A-Form DNA (A-DNA)IBA 01/2018
1	phosphomannopentaose sulfateIBA 10/2017
1	Heparin (Liquaemin)FDA LinkGeneric 10/2017
1	Heparitin Sulfate (Heparan Sulfate)IBA 10/2017
1	Mannose (D-Mannose)IBA 10/2017
1	OligosaccharidesIBA 10/2017
1	Immunoglobulin A (IgA)IBA 10/2014
1	AlarminsIBA 08/2014
1	EpitopesIBA 01/2014
1	STAT6 Transcription FactorIBA 01/2013
1	Anti-Infective Agents (Microbicides)IBA 11/2012
1	Interleukin-2 (IL2)IBA 08/2011
1	Interleukin-12 (IL 12)IBA 08/2011
1	Toll-Like Receptors (Toll-Like Receptor)IBA 08/2011
1	HIV AntigensIBA 01/2006
1	DNA VaccinesIBA 10/2005

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2014